The bed-in-a-box industry is changing the way people shop for mattresses. Consumer Reports' Mary Beth Quirk joins Cheddar to discuss the non-profit's cover story about the evolving state of the mattress industry. Despite getting all the headlines, bed-in-a-box brands still only account for a small fraction of the market. Quirk tells us why the phenomenon stills feels like a novelty for most shoppers, despite being around for a few years. She also explains the challenge they pose to Consumer Reports' "try before you buy" policy. Helpful return policies make the practice a viable one for beds ordered online. The online consumer editor speaks to which types of mattresses get the highest marks when it comes to quality. She also tells us whether the showroom model is working out for digital retailers. Quirk considers whether the bed-in-a-box industry is a bubble primed to pop, with almost 200 brands and counting.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More